Direct answer:FDA issued direct final rules on non-clinical test terms in September 2026 and accompanying proposed rules as an alternative procedure in the same issue. It updates the terminology in the drug and biological product development legislation so that non-clinical tests can cover non-animal new methods (NAMs) and non-human body research; The FDA note states that it does not impose a method or change the evidentiary standard.The nature of the document, the current status and the business recommendations are set out below; Specific products should be judged in the official language.
What is this file, at what stage?
The regulatory document and its status referred to in this paper is based on the original FDA page listing. The updating of terminology does not amount to the mandatory adoption of NAMs, nor does it imply a change in the evidentiary standard; The direct final rule is to be distinguished from the proposed rule.
A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.
Which enterprises and products need attention?
Applicants for research and development of pharmaceuticals and biological products, non-clinical research institutions and regulatory teams.
It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.
Where is the change from what was previously requested?
The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.
FDA issued direct final rules on non-clinical test terms in September 2026 and accompanying proposed rules as an alternative procedure in the same issue. It updates the terminology in the drug and biological product development legislation so that non-clinical tests can cover non-animal new methods (NAMs) and non-human body research; The FDA note states that it does not impose a method or change the evidentiary standard.
FDA Updates the statutory language to reflect the scope of non-clinical tests, with examples including cell models, organ chips and computational models such as NAMs. The type of non-clinical evidence used still needs to be assessed in conjunction with products, stages of development, scientific validity and specific declaration requirements.
- Finds the official text of the final and accompanying proposed rules in Federal Register.
- Confirm whether the rules are in force as announced, whether significant adverse comments have been received or subsequently amended.
- Distinguishing general terminology updates from non-clinical research requirements in specific product development projects.
- If NAMs are planned to be used, document the applicability of the model, the basis for validation, the scientific justification and communication with the regulatory authorities.
Key dates and transitional arrangements
The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.
- September 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.
How can Chinese companies prepare?
- Assessment of the scientific applicability, certification status, product development stage and declaration of evidentiary needs of NAMs; Verify the status of the direct final rules and the proposed accompanying rules on a case-by-case basis.
- Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
- If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.
For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.
Exceptions, pending confirmations and common misreading
- The updating of terminology does not amount to the mandatory adoption of NAMs, nor does it imply a change in the evidentiary standard; The direct final rule is to be distinguished from the proposed rule.
- When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
- Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.
Official information and reconciliation records
- FDA:New Approach Methodologies (NAMs)
- FDA: Actions to Accelerate and Moderize Criminal Development (including September 2026 rule note)
- FDA: Guides database (for checking current file status)
(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.
Next
Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.